Zydus has announced biological therapy ZRC-3308, used to treat mild COVID-19. The pharmaceutical company now seeks DCGI (Drugs Controller General of India) nod to undertake clinical trials for monoclonal antibodies cocktail that can neutralise Covid infection.
In a statement, Dr Sharvil Patel, Managing Director of Cadila Healthcare Limited, said they believe that ‘biological therapy’ ZRC-3308 – ‘a cocktail of two SARS-CoV-2-neutralizing monoclonal antibodies (mAbs)’, has the potential to address concerns abut the progression of the disease.
In a press release, the pharmaceutical company said the ZRC-3308 is designed to have a “long half-life providing protection for a long period of time” and has “reduced immune-effector to minimize potential tissue-damaging side effects of virus neutralising monoclonal antibodies thereby providing a safer product.”
Explore the profound effects of excessive screen time on your child’s behavior and development. Discover…
Discover how simple daily changes in your diet and lifestyle can significantly improve your heart…
This article explores the common misconception that brain tumours primarily affect older adults, revealing the…
The first-ever ovarian cancer vaccine is poised to change the landscape of women's health by…
As dengue and chikungunya cases rise in Delhi during the monsoon season, understanding prevention strategies…
Skincare is a significant concern for women (and increasingly, men), with the quest for perfect,…